CY1122868T1 - Φαρμακευτικες συνθεσεις που περιεχουν 2-αμινο-2-[2-(4-οκτυλοφαινυλ)αιθυλ]προπανο-1,3-διολη - Google Patents

Φαρμακευτικες συνθεσεις που περιεχουν 2-αμινο-2-[2-(4-οκτυλοφαινυλ)αιθυλ]προπανο-1,3-διολη

Info

Publication number
CY1122868T1
CY1122868T1 CY20201100169T CY201100169T CY1122868T1 CY 1122868 T1 CY1122868 T1 CY 1122868T1 CY 20201100169 T CY20201100169 T CY 20201100169T CY 201100169 T CY201100169 T CY 201100169T CY 1122868 T1 CY1122868 T1 CY 1122868T1
Authority
CY
Cyprus
Prior art keywords
octylphenyl
diol
propane
ethyl
amino
Prior art date
Application number
CY20201100169T
Other languages
English (en)
Inventor
Supriya Rane
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45953284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122868(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1122868T1 publication Critical patent/CY1122868T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

Μια στερεή φαρμακευτική σύνθεση κατάλληλη για από του στόματος χορήγηση, η οποίο περιλαμβάνει: (α) έναν διαμορφωτή υποδοχέα S1Ρ, (β) ένα πληρωτικό υλικό, και (γ) μια κυκλοδεξτρίνη.
CY20201100169T 2011-04-01 2020-02-24 Φαρμακευτικες συνθεσεις που περιεχουν 2-αμινο-2-[2-(4-οκτυλοφαινυλ)αιθυλ]προπανο-1,3-διολη CY1122868T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161470747P 2011-04-01 2011-04-01
US201161545835P 2011-10-11 2011-10-11
EP12714163.8A EP2694037B1 (en) 2011-04-01 2012-03-30 Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
PCT/US2012/031340 WO2012135561A1 (en) 2011-04-01 2012-03-30 Formulations comprising 2 -amino- 2- [2- (4 - octylphenyl) ethyl] propane -1, 3 - diol

Publications (1)

Publication Number Publication Date
CY1122868T1 true CY1122868T1 (el) 2021-05-05

Family

ID=45953284

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171100045T CY1118423T1 (el) 2011-04-01 2017-01-12 Σκευασματα που περιλαμβανουν την 2-αμινο-2-[2-(4-οκτυλ-φαινυλ)αιθυλ]προπανο-1,3-διολη
CY20201100169T CY1122868T1 (el) 2011-04-01 2020-02-24 Φαρμακευτικες συνθεσεις που περιεχουν 2-αμινο-2-[2-(4-οκτυλοφαινυλ)αιθυλ]προπανο-1,3-διολη

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20171100045T CY1118423T1 (el) 2011-04-01 2017-01-12 Σκευασματα που περιλαμβανουν την 2-αμινο-2-[2-(4-οκτυλ-φαινυλ)αιθυλ]προπανο-1,3-διολη

Country Status (35)

Country Link
US (5) US9592208B2 (el)
EP (2) EP2694037B1 (el)
JP (1) JP6019101B2 (el)
KR (1) KR102027014B1 (el)
CN (1) CN103476400B (el)
AR (1) AR085749A1 (el)
AU (1) AU2012236357B2 (el)
BR (1) BR112013024430B1 (el)
CA (1) CA2831600C (el)
CL (1) CL2013002810A1 (el)
CO (1) CO6771459A2 (el)
CY (2) CY1118423T1 (el)
DK (2) DK3143990T3 (el)
EA (2) EA027721B1 (el)
EC (1) ECSP13012912A (el)
ES (2) ES2773482T3 (el)
GT (1) GT201300227A (el)
HK (1) HK1190309A1 (el)
HR (2) HRP20170021T1 (el)
HU (1) HUE031286T2 (el)
IL (1) IL228250B (el)
JO (1) JO3177B1 (el)
LT (2) LT2694037T (el)
MA (1) MA34981B1 (el)
MX (1) MX342522B (el)
MY (2) MY163746A (el)
PE (2) PE20170913A1 (el)
PL (2) PL3143990T3 (el)
PT (2) PT2694037T (el)
RS (1) RS59917B1 (el)
SG (1) SG193256A1 (el)
SI (2) SI3143990T1 (el)
TW (1) TWI528958B (el)
WO (1) WO2012135561A1 (el)
ZA (1) ZA201306636B (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
CN103222966A (zh) * 2013-04-01 2013-07-31 北京万全德众医药生物技术有限公司 一种含有盐酸芬戈莫德的固体药物组合物及其制备方法
MX2016001422A (es) 2013-07-29 2016-10-05 Aizant Drug Res Solutions Pvt Ltd Composicion farmaceutica de fingolimod.
US20170231928A1 (en) * 2014-08-22 2017-08-17 Sunshine Lake Pharma Co., Ltd. Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en) 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
CN107530301A (zh) * 2015-01-20 2018-01-02 汉达医药有限责任公司 稳定的固体芬戈莫德剂型
EP3419607B1 (en) 2017-03-29 2019-11-20 Deva Holding Anonim Sirketi Stable formulations of fingolimod
WO2021158848A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor agonist
US11135197B2 (en) 2020-02-07 2021-10-05 Argentum Pharmaceuticals Llc Dosage regimen of an S1P receptor modulator

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
DE122011100012I1 (de) 1992-10-21 2011-10-20 Mitsubishi Tanabe Pharma Corp 2-Amino-1, 3-propandiolverbindung und immunosuppressium.
HU224814B1 (en) 1995-12-28 2006-02-28 Mitsubishi Pharma Corp Use of propane-1,3-diol derivative for the preparation of a medicament useful for the topical treating of inflammatory and immune diseases
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
EP2030614A1 (en) 1997-02-27 2009-03-04 Novartis AG Pharmaceutical Composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol and a lecithin
NZ500713A (en) 1997-04-04 2000-07-28 Yoshitomi Pharmaceutical 2-aminopropane-1,3-diol compounds and medicinal use thereof
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP4627356B2 (ja) 1999-06-30 2011-02-09 松森　　昭 ウイルス性心筋炎の予防または治療薬剤
AU2001285331B2 (en) 2000-08-31 2006-04-06 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
PE20130200A1 (es) 2003-04-08 2013-03-09 Novartis Ag Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar
JP4861177B2 (ja) * 2003-09-12 2012-01-25 ニューロノバ エービー 神経系の障害の処置
MX2007006706A (es) 2004-12-06 2007-10-18 Univ Virginia Analogos de esfingosina 1-fosfato amida de arilo.
GB0502358D0 (en) * 2005-02-04 2005-03-16 Novartis Ag Organic compounds
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
PL3103448T3 (pl) * 2006-09-26 2019-12-31 Novartis Ag Kompozycje farmaceutyczne zawierające modulator S1P
CA2672727A1 (en) 2006-12-21 2008-07-03 Abbott Laboratories Sphingosine-1-phosphate receptor agonist and antagonist compounds
WO2009048993A2 (en) * 2007-10-12 2009-04-16 Novartis Ag Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
US8680146B2 (en) 2008-11-11 2014-03-25 Novartis Ag Organic compounds
HUE026869T2 (en) 2008-12-22 2016-08-29 Novartis Ag Dosing regimen for fingolimod for the treatment of multiple sclerosis

Also Published As

Publication number Publication date
US20170135967A1 (en) 2017-05-18
AR085749A1 (es) 2013-10-23
CA2831600A1 (en) 2012-10-04
DK3143990T3 (da) 2020-03-02
MY175633A (en) 2020-07-02
US20140371323A1 (en) 2014-12-18
ES2610966T3 (es) 2017-05-04
HRP20170021T1 (hr) 2017-03-10
HRP20200249T1 (hr) 2020-05-15
TW201244711A (en) 2012-11-16
MA34981B1 (fr) 2014-03-01
PL3143990T3 (pl) 2020-05-18
EA201790436A2 (ru) 2017-10-31
JO3177B1 (ar) 2018-03-08
CN103476400A (zh) 2013-12-25
EP2694037B1 (en) 2016-10-12
PT2694037T (pt) 2017-01-17
KR20140014194A (ko) 2014-02-05
CY1118423T1 (el) 2017-06-28
TWI528958B (zh) 2016-04-11
PL2694037T3 (pl) 2017-05-31
CO6771459A2 (es) 2013-10-15
GT201300227A (es) 2015-05-05
BR112013024430A2 (pt) 2016-12-20
EA035686B1 (ru) 2020-07-27
LT2694037T (lt) 2017-01-10
KR102027014B1 (ko) 2019-09-30
RS59917B1 (sr) 2020-03-31
MX2013011415A (es) 2013-12-09
IL228250B (en) 2020-09-30
US20190247335A1 (en) 2019-08-15
DK2694037T3 (en) 2017-01-16
MX342522B (es) 2016-10-03
PT3143990T (pt) 2020-03-04
WO2012135561A1 (en) 2012-10-04
SI3143990T1 (sl) 2020-03-31
AU2012236357A1 (en) 2013-10-10
US20180193291A1 (en) 2018-07-12
ECSP13012912A (es) 2013-11-29
PE20140162A1 (es) 2014-02-12
PE20170913A1 (es) 2017-07-12
JP6019101B2 (ja) 2016-11-02
ZA201306636B (en) 2014-05-28
US20200276137A1 (en) 2020-09-03
ES2773482T3 (es) 2020-07-13
EA201391442A1 (ru) 2014-04-30
HK1190309A1 (zh) 2014-07-04
CN103476400B (zh) 2016-11-09
AU2012236357B2 (en) 2016-03-10
EA027721B1 (ru) 2017-08-31
JP2014509652A (ja) 2014-04-21
MY163746A (en) 2017-10-31
US9592208B2 (en) 2017-03-14
SI2694037T1 (sl) 2017-01-31
EP3143990B1 (en) 2019-11-27
BR112013024430B1 (pt) 2022-02-08
EP2694037A1 (en) 2014-02-12
HUE031286T2 (hu) 2017-06-28
SG193256A1 (en) 2013-10-30
CL2013002810A1 (es) 2014-02-14
EA201790436A3 (ru) 2018-03-30
LT3143990T (lt) 2020-02-25
CA2831600C (en) 2020-04-21
EP3143990A1 (en) 2017-03-22
NZ615023A (en) 2016-07-29

Similar Documents

Publication Publication Date Title
CY1122868T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν 2-αμινο-2-[2-(4-οκτυλοφαινυλ)αιθυλ]προπανο-1,3-διολη
CY1122786T1 (el) Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
CY1119798T1 (el) Μορφη iv υδροχλωρικης ιβαμπραδινης
CY1118350T1 (el) Μορφες δοσολογιας για ληψη απο το στομα που περιλαμβανουν οξεικη λικαρβαζεπινη
PE20120337A1 (es) Producto conteniendo formas de dosificacion oral de fingolimod
BR112013025969A2 (pt) forma de dose unitária para administração oral
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
EA201290984A1 (ru) Гелеобразные фармацевтические композиции, препятствующие злоупотреблению
ECSP12012208A (es) Formulaciones orales y sales lipofílicas de metilnaltrexona
BR112014022780A8 (pt) composto modulador de receptor de fígado x, composição farmacêutica que o compreende e seu uso
CY1118976T1 (el) Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης
EA201170512A1 (ru) Композиция для перорального введения
CR11744A (es) Formulacion liquida para deferiprona con gusto agradable al paladar
UY35751A (es) Moduladores negativos de n-arilmetilo sulfonamida de nr2a
UY35750A (es) Moduladores octahidro-ciclopenta[c] pirrol negativos de nr2b
AR118842A2 (es) Composición farmacéutica que contiene tamoxifen y endoxifen y procedimiento para prepararla
UY34080A (es) Composición farmacéutica para administración oral que comprende fexofenadina y métodos de preparación
TN2013000396A1 (en) Formulations comprising 2 -amino- 2- [2- (4 - octylphenyl) ethyl] propane -1, 3 - diol
BRPI0919475A2 (pt) composição farmacêutica para administração oral
CU20120115A7 (es) Composición farmacéutica sólida para administración bucal de agomelatina
AR124661A2 (es) Formulaciones
BR112013027089A2 (pt) composto, composição farmacêutica e método para usar um composto
CY1120838T1 (el) Μεθοδος χορηγησης 4-((1r,3s)-6-xλωpo-3-φainyλo-inδan-1-yλo)-1,2,2-τριμεθυλο-πιπεραζινης και των αλατων αυτης στην αντιμετωπιση σχιζοφρενειας
CL2008002872A1 (es) Material alimenticio para peces que comprende una secuencia de aminoacidos recombinante derivada de plantas; y metodo para preparar una formulacion de vacuna oral para peces (div. sol. 2601-03).